Skip to content
OpenCapital
Get started

Stoke Therapeutics, Inc. STOK Q2 2025 earnings

Reported August 12, 2025 · After market close

Revenue$13.8MBeat by $8.5MDiluted EPS-$0.40Beat by $0.17
Revenue estimate$5.4M
EPS estimate-$0.57

Next report

Aug 11, 2026 (in a month)
Revenue estimate$5.4M
EPS estimate-$0.82

Financials

Q2 2025

Income statement

See full
Revenue$13.8M+186%
Operating income-$27.3M+7.0%
Net income-$23.5M+8.6%
EPS (diluted)-$0.40+13.0%

Balance sheet

See full
Cash & equivalents$101.5M-47.6%
Total debt$5.3M-9.3%
Total equity$334.9M+38.0%
Total assets$384.5M+24.9%

Cash flow

See full
CapEx$154.0K+235%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$628.41M+0.6%
Enterprise value$532.22M+21.7%
P/E12×—
P/S3.1×-38.1×

Profitability

See full
Operating margin20.2%+10.2pp
Net margin26.3%+13.4pp

Returns & leverage

See full
Return on equity18.2%+10.5pp
Debt / equity0×0.0×
Current ratio7×+0.3×

Versus estimates

Revenue

Q1 2026$6.2MMiss by $254.3KQ4 2025$1.4MMiss by $4.4MQ3 2025$10.6MBeat by $6.1M
Q2 2025$13.8MBeat by $8.5M
Q1 2025$158.6MBeat by $127.1MQ4 2024$22.6MBeat by $18.8M

Diluted EPS

Q1 2026-$0.79Beat by $0.01Q4 2025-$0.97Miss by $0.22Q3 2025-$0.65Miss by $0.11
Q2 2025-$0.40Beat by $0.17
Q1 2025$1.90Beat by $2.27Q4 2024-$0.18Beat by $0.33

Ask the moment Stoke Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Stoke Therapeutics, Inc. report Q2 2025 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q2 2025 earnings on August 12, 2025 after market close.
What were Stoke Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $13.8M and diluted EPS of $-0.40 for Q2 2025.
Did Stoke Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $5.4M by $8.5M. EPS beat the consensus estimate of $-0.57 by $0.17.
How did Stoke Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 186.0% from $4.8M a year earlier and diluted EPS grew 13.0% from $-0.46.
Where can I find Stoke Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-107332) directly on SEC EDGAR. The filing index links above go to sec.gov.